Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,159 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (563)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02128282 | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | completed | Phase 1 / Phase 2 | 127 | Senhwa Biosciences, Inc.INDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT03644173 | Personal Resilience Empowerment Program Study | completed | N/A | 37 | Hackensack Meridian HealthOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT02507765 |
| Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery |
| completed |
| Phase 1 |
| 16 |
| Ohio State University Comprehensive Cancer CenterOTHER |
| 1 |
| Oct 13, 2021 |
| clinicaltrials |
| NCT02115542 | Single Agent Regorafenib in Refractory Advanced Biliary Cancers | completed | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT03109886 | Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 31 | Tiziana Life Sciences LTDINDUSTRY | 3 | Oct 12, 2021 | clinicaltrials |
| NCT04264962 | Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter(YYFZJDTRHCLT3D) | completed | Early Phase 1 | 300 | Beijing Ditan HospitalOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT01387503 | Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging | completed | N/A | 74 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 11, 2021 | clinicaltrials |
| NCT05045573 | Pathological Results of Aggressive Hepatocellular Carcinomas Treated Using SIRT(PAHCHS) | completed | — | 28 | University Hospital, MontpellierOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT00892658 | Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP) | completed | Phase 1 | 24 | University Health Network, TorontoOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT00914355 | Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2) | completed | Phase 2 | 92 | University Health Network, TorontoOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT01642446 | Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension | completed | N/A | 160 | Sun Yat-sen UniversityOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT03041662 | Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)(PSC) | completed | — | 620 | Karolinska University HospitalOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT04891874 | Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI | completed | N/A | 76 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT05038397 | A Study to Evaluate Efficacy and Safety of TheraSphere and Resection Combination Therapy in Patients With Single Large ((> 5cm, Long Diameter ) Hepatocellular Carcinoma : Exploratory Trial(Therasphere) | completed | N/A | 30 | MedicalExcellenceOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT02329106 | Percutaneous Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02332551 | Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02333773 | Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli(IRE) | completed | N/A | 15 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02352935 | Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function | completed | N/A | 15 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT04301999 | Clinical Effect and Safety of PDT and RFA for Unresectable EHCC | completed | N/A | 67 | First People's Hospital of HangzhouOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT00335829 | Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 26 | Yale UniversityOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02089763 | Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer | completed | Phase 2 | 27 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Aug 9, 2021 | clinicaltrials |
| NCT02878109 | DCE-MRI for Assessment of Response to TACE of HCC(DCE-MRI) | completed | — | 40 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT02631590 | Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma | completed | Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT02774161 | B-mode Ultrasound Imaging in Detecting Early Liver Cancer | completed | N/A | 45 | Stanford UniversityOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT03093870 | Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer(TreeTopp) | completed | Phase 2 / Phase 3 | 151 | ASLAN PharmaceuticalsOTHER | 11 | Aug 3, 2021 | clinicaltrials |
| NCT01126463 | 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas(LIP-RE-I) | completed | Phase 1 | 16 | Center Eugene MarquisOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT03767764 | Yliver as a Test to Early Diagnose HCC(YliverDIAG) | completed | — | 190 | Corporacion Parc TauliOTHER | 1 | Jul 29, 2021 | clinicaltrials |
| NCT02291133 | Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)(ECT-HCC) | completed | Phase 1 / Phase 2 | 25 | Masa BosnjakOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT03645655 | PIVKA-II Combined With Alpha-Fetoprotein for Diagnostic and Prognostic Value of Hepatic Tumors in Infants(PIVKA-II) | completed | — | 257 | Shanghai Children's Medical CenterOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT00261378 | Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation(PRECISIONV) | completed | Phase 2 | 212 | Boston Scientific CorporationINDUSTRY | 4 | Jul 21, 2021 | clinicaltrials |
| NCT03200171 | Effect of DAAs on Behavior of HCC in HCV Patients | completed | — | 300 | Al-Azhar UniversityOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT03291379 | Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies(VEROnA) | completed | Early Phase 1 | 8 | Boston Scientific CorporationINDUSTRY | 1 | Jul 19, 2021 | clinicaltrials |
| NCT03707080 | Direct Acting Antiviral-Post Authorization Safety Study | completed | — | 42 | Target PharmaSolutions, Inc.INDUSTRY | 5 | Jul 6, 2021 | clinicaltrials |
| NCT04269499 | Real-time Imaging of Holmium Radioembolization: a Feasibility Study(Emeritus) | completed | N/A | 6 | Radboud University Medical CenterOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT03245190 | Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 27 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jun 18, 2021 | clinicaltrials |
| NCT02292173 | Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT03267641 | Prospective Cohort Study on the Clinical Trajectory of Resected Hepatocellular Carcinoma(PLANET) | completed | — | 86 | National Cancer Centre, SingaporeOTHER | 4 | Jun 9, 2021 | clinicaltrials |
| NCT04656249 | Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer(LENABC) | completed | Phase 2 | 46 | Peking Union Medical College HospitalOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04642664 | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer(ACABC) | completed | Phase 2 | 22 | Peking Union Medical College HospitalOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT01655693 | Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma(ReLive) | completed | Phase 3 | 397 | Valerio TherapeuticsINDUSTRY | 11 | Jun 2, 2021 | clinicaltrials |
| NCT01271504 | E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 102 | Eisai Inc.INDUSTRY | 6 | May 12, 2021 | clinicaltrials |
| NCT02859324 | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 4 | May 11, 2021 | clinicaltrials |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib(CELESTIAL) | completed | Phase 3 | 707 | ExelixisINDUSTRY | 19 | May 6, 2021 | clinicaltrials |
| NCT02472249 | Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC | completed | Phase 4 | 10 | University Health Network, TorontoOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02973204 | Circulating Tumor Cells and Tumor DNA in HCC and NET | completed | — | 167 | University of AarhusOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT00536601 | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | completed | N/A | 174 | Roswell Park Cancer InstituteOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT03295006 | A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC(TARGET) | completed | — | 209 | Boston Scientific CorporationINDUSTRY | 8 | Apr 21, 2021 | clinicaltrials |
| NCT03706742 | STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention | completed | N/A | 12,386 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT03741088 | Study to Evaluate VORTX Rx (Theresa)(Theresa) | completed | N/A | 8 | HistoSonics, Inc.INDUSTRY | 1 | Apr 20, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Oct 22, 2021source: clinicaltrials